First RayPilot® prostate tracking system installed in UK

In the last week of November, the first RayPilot® system in Great Britain was installed at the Edinburgh Cancer Center at Western General Hospital in Edinburgh, a university hospital in the NHS public healthcare system.

The hospital will use the RayPilot® electromagnetic tumor tracking system when starting SBRT/extreme hypofractionated prostate protocols.

In addition to using RayPilot® for high precision prostate cancer treatment, the clinic also intends to conduct R&D work with the aim to broaden the functionality as well as working with other tumor sites where organ motion is crucial.

Installation and training was conducted during two afternoons by Micropos staff without disturbing the clinical work at the radiotherapy department.

Treatment start is expected during the first quarter of 2018.

Micropos TEAM Edinburgh Cancer Centre 201711

Micropos team during the installation of RayPilot®: Oscar Sjöberg, Andreas Bergqvist och Hanna Syrén together with the great team from The Edinburgh Cancer Center.

For additional information:

Tomas Gustafsson, CEO, Micropos Medical AB (publ), +46-31-760 80 05

About Micropos Medical AB (publ):

Micropos Medical AB (publ) (www.micropos.se) is a Swedish company that has developed the RayPilot® system, which is an electromagnetic positioning and real time tracking system for a fast and objective set-up and for continuous positioning during radiotherapy. A precise and safe localization of the tumor can dramatically improve the outcome of the treatment, particularly for hypofractionated protocols. The RayPilot® system consists mainly of three parts; one transmitter that is placed close by the tumor, a receiving system that is placed directly on the treatment couchtop and software that continuously shows the precise tumor location, and hence where to focus the linac beam. RayPilot® has a unique gating solution qualified and compatible for use with Varian’s Clinac® iX linear accelerators and Trilogy® systems. Micropos develops an upcoming RayPilot® transmitter for positioning, in-situ dosimetry and automatic patient identification. RayPilot® is CE certified for prostate and surface use. Follow us on Facebook, www.facebook.com/MicroposMedical. The Micropos share is traded under the stock ticker MPOS.

 

Search the website

×